Inbiomotion

inbiomotion.com ↗ ·Barcelona ·Series A

Inbiomotion is a Barcelona-based precision oncology diagnostics company that spun off from IRB Barcelona and ICREA in 2011. It developed the MAF Test®, a companion diagnostic biomarker test that identifies which early breast cancer patients are likely to benefit from adjuvant bisphosphonate therapy. The MAF Test® is now commercially available, with distribution agreements in South Korea, Sub-Saharan Africa, and Italy.

Founded

2011

Founders

Total funds raised

€4.2M+

SectorsPrecision Oncology, Diagnostics, Companion Diagnostics, Biotech Start-up MapHealthtech & Bio › Diagnostics & precision medicine testing

Suggest a correction

Founders

Roger Gomis

Founder & Chief Scientific Officer

Global models 5

GRAIL

United States · grail.com ↗

Molecular diagnostics company using genomic biomarkers for early cancer detection, the same biomarker-driven precision oncology model as Inbiomotion's MAF Test.

$2BComparable

Freenome

United States · www.freenome.com ↗

Develops blood-based biomarker tests to guide cancer screening and treatment decisions, mirroring Inbiomotion's biomarker diagnostic approach.

$1.1BComparable

Guardant Health

United States · guardanthealth.com ↗

Liquid biopsy company providing molecular biomarker tests that guide oncology treatment decisions, the same companion-diagnostic model.

$550MComparable

Natera

United States · www.natera.com ↗

Genetic and molecular diagnostics company offering biomarker-based tests used to personalize cancer treatment, similar to Inbiomotion's precision medicine model.

$152MComparable

Foundation Medicine

United States · www.foundationmedicine.com ↗

Genomic profiling company whose tests stratify cancer patients by biomarker status to guide treatment, directly comparable to Inbiomotion's MAF Test approach.

$96.5MComparable

In the same niche 48 others

See all in the Start-ups Map →

Universal Diagnostics

Venture Debt · €25.7M

Biohope

Madrid

No stage disclosed · €15M

iPremom

Valencia

Seed · €15M

+42 more →

Notes: Most funded first

Investors 6

Open as list →

Ysios Capital

ysioscapital.com

2 rounds, led 1 · 2012–16 Spain

Alta Life Sciences

www.altals.com

Led round 2021 Spain

Criteria Capital Risc

www.caixacapitalrisc.es

Led Series A 2016 Spain

Institut Català de Finances

icf.cat

Round 2021 Spain

Fundació Vila Casas

www.fundaciovilacasas.com ↗

2 rounds · 2012–16 Spain

JVRisk Technologies

Series A 2012 Spain

Funding rounds 3

Date	Round	Amount	Lead
2021-01-21	No stage disclosed	—	Alta Life Sciences +1 more
2016-03-09	Series A (estimated)	€2.2M	Caixa Capital Risc +2 more
2012-06-28	Series A	€2M	Ysios Capital +2 more

News 8

Open as list →

Published	Article
2026-05-21	Inbiomotion and HJ HyupJin enter a partnership for MAF Test® in South Korea ↗ Ysios Capital 2026-05-21
2026-01-15	Inbiomotion's MAF Test® included in 2025 SEOM-GEICAM-SOLTI Clinical Practice Guidelines for Early-Stage Breast Cancer, further supporting its clinical utility ↗ IRB Barcelona 2026-01-15
2025-07-17	Top Spanish hospitals adopt the MAF Test to improve breast cancer treatment ↗ Ysios Capital 2025-07-17
2024-10-09	Inbiomotion and SPA - Società Prodotti Antibiotici (SPA Farma) sign an exclusive agreement for MAF Test® in Italy ↗ IRB Barcelona 2024-10-09
2024-02-08	Inbiomotion and Source BioScience sign an exclusive agreement for MAF Test® in United Kingdom and Ireland ↗ Ysios Capital 2024-02-08
2023-12-13	Inbiomotion and The Scientific Group sign an exclusive distribution agreement of MAF Test® for the Sub-Saharan Africa ↗ Ysios Capital 2023-12-13
2023-11-10	Publication in Nature Cell Biology deciphers the mechanism by which the MAF protein promotes breast cancer metastasis ↗ Ysios Capital 2023-11-10
2023-09-28	Palex and Inbiomotion introduce pioneering test to aid oncologists in predicting recurrence and survival rates in breast cancer patients ↗ Newswise 2023-09-28